AngioDynamics, Inc. (NASDAQ:ANGO) today announced that the company will release fiscal 2007 third quarter results after the market closes on Tuesday, March 27, 2007.
Eamonn P. Hobbs, president and chief executive officer, and Joseph G. Gerardi, chief financial officer, will host an investment community conference call beginning at 4:30 p.m. Eastern time on March 27th to discuss these results and to answer questions.
To participate in the live call by telephone, please dial 800-798-2801 from the U.S., or for international callers, please dial 617-614-6205. Please enter the passcode: 49311604.
Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of AngioDynamics’ web site at http://investor.angiodynamics.com. To listen to the live call, please go to the Web site 15 minutes prior to its start to register, download, and install the necessary audio software.
A replay will be available on the Web site. A telephone replay will be available from 6:30 p.m. Eastern time on March 27, 2007 through 11:59 p.m. Eastern time on April 3 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering the passcode: 50281930.
AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive diagnosis and treatment of cancer and peripheral vascular disease. The company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 3, 2006, may affect the actual results achieved by the Company.